Objective-Recent studies have shown that angiotensin II (Ang II) plays a critical role in the pathogenesis and progression of hypertensive kidney disease. However, the signaling mechanisms are poorly understood. In this study, we investigated the role of CXCR6 in Ang II-induced renal injury and fibrosis. Approach and Results-Wild-type and CXCR6-green fluorescent protein (GFP) knockin mice were treated with Ang II via subcutaneous osmotic minipumps at 1500 ng/kg per minute after unilateral nephrectomy for ≤4 weeks. Wild-type and CXCR6-GFP knockin mice had virtually identical blood pressure at baseline. Ang II treatment led to an increase in blood pressure that was similar between wild-type and CXCR6-GFP knockin mice. CXCR6-GFP knockin mice were protected from Ang II-induced renal dysfunction, proteinuria, and fibrosis. CXCR6-GFP knockin mice accumulated fewer bone marrow-derived fibroblasts and myofibroblasts and produced less extracellular matrix protein in the kidneys after Ang II treatment. Furthermore, CXCR6-GFP knockin mice exhibited fewer F4/80 + macrophages and CD3 + T cells and expressed less proinflammatory cytokines in the kidneys after Ang II treatment. Finally, wild-type mice engrafted with CXCR6 −/− bone marrow cells displayed fewer bone marrow-derived fibroblasts, macrophages, and T cells in the kidney after Ang II treatment when compared with wild-type mice engrafted with CXCR6 +/+ bone marrow cells.
C hronic kidney disease (CKD) is a growing public health problem in the world. Hypertension is a major cause of CKD. A prominent pathological feature in patients with CKD is inflammation, tubular atrophy, and interstitial fibrosis. The degree of renal fibrosis correlates well with the prognosis of kidney disease. 1 Renal interstitial fibrosis is characterized by massive fibroblast activation and excessive production and deposition of extracellular matrix, which leads to the destruction of renal parenchyma and progressive loss of kidney function. The current therapeutic options in the clinical settings for this devastating condition are limited and often ineffective except for dialysis or kidney transplantation, thus making chronic kidney failure one of the most expensive diseases to treat on a per-patient basis. 2 Despite improvement in the knowledge of diverse aspects related to CKD, the pathogenesis and the initial molecular events leading to chronic renal fibrosis and eventually chronic renal failure remain elusive. Therefore, a better understanding of the cellular and molecular mechanisms underlying the pathogenesis of CKD is essential for developing effective strategies to treat this devastating disorder and prevent its progression.
A large body of evidence indicates that activation of the renin-angiotensin system plays a central role in initiation and progression of CKD through regulation of inflammation and fibrosis. 3 The underlying mechanisms involved in angiotensin II (Ang II)-induced kidney disease are incompletely understood. Recent studies have shown that inflammatory and immune cell infiltration and altered chemokine production are characteristic for hypertensive kidney damage. 4, 5 The infiltration of circulating cells into sites of injury is mediated by locally produced chemokines through interaction with their respective receptors. However, the mechanism resulting in infiltration of these cells in hypertension remains incompletely understood.
We have recently shown that CXCL16 is induced in the kidney in response to Ang II, and genetic deletion of CXCL16 suppresses Ang II-induced renal injury and fibrosis. 6 CXCR6 is the receptor for CXCL16, which is expressed in T cells, monocytes, and myeloid fibroblasts. [7] [8] [9] In this study, we investigated the role of CXCR6 in leukocyte recruitment and renal injury in Ang II-induced hypertensive kidney disease.
Materials and Methods
Materials and Methods are available in the online-only Supplement. 10
Results

Blood Pressure
There were no significant differences in blood pressure among the 4 groups at baseline. Ang II treatment increased blood pressure in both WT and CXCR6-green fluorescent protein (GFP) knockin mice with no differences between the 2 treatment groups ( Figure 1A ).
Renal Function
Treatment with Ang II for 4 weeks caused kidney dysfunction in WT mice as reflected by significant elevation of blood urea nitrogen. Kidney function was preserved in CXCR6-GFP knockin mice with blood urea nitrogen markedly lower than WT mice ( Figure 1B ).
Albuminuria
WT mice developed massive albuminuria after Ang II treatment for 4 weeks, whereas Ang II-treated CXCR6-GFP knockin mice produced significantly less albuminuria ( Figure 1C ).
Kidney Injury and Fibrosis
To assess the effect of CXCR6 disruption on Ang II-induced kidney damage, kidney sections were stained with Periodic Acid Schiff and scored for histological injury after 4 weeks of saline or Ang II infusion ( Figure 2A ; Table I in the online-only  Data Supplement) . On a semiquantitative scale that includes glomerulosclerosis, interstitial disease, fibrosis, and vascular injury, the 2 saline-infused groups had minimal kidney damage. Ang II caused a marked increase in the severity of kidney injury in the WT mice, which was substantially reduced in CXCR6-GFP knockin mice. Sirius red staining showed that Ang IItreated WT mice developed significant collagen deposition in the kidney when compared with saline-treated WT mice. These fibrotic responses were significantly reduced in CXCR6-GFP knockin mice with chronic Ang II infusion ( Figure 2B and 2C).
We next examined the effect of CXCR6 disruption on the expression of collagen I and fibronectin, 2 major components of extracellular matrix. Immunofluorescence staining demonstrated that CXCR6 disruption attenuated the upregulation of collagen I ( Figure 3A and 3B) and fibronectin ( Figure 3C and 3D). Similar results were obtained with Western blot analysis ( Figure 3E and 3F).
Myeloid Fibroblasts Accumulation and Myofibroblast Formation
Recent evidence indicates that myeloid fibroblasts contribute significantly to the pathogenesis of renal fibrosis and circulating fibroblast precursors expressed CXCR6. 9, [11] [12] [13] [14] To examine the effect of CXCR6 disruption on the accumulation of myeloid fibroblasts in the kidney, WT and CXCR6-GFP knockin mice were infused with vehicle or Ang II for 2 weeks. The 2-week model of Ang II infusion was chosen because we and others have shown that cellular infiltration precedes the development of target organ injury. 9, 15, 16 Kidney sections were stained for CD45 and pro-collagen I and examined with a fluorescence microscope. The number of bone marrow-derived fibroblasts dual positive for CD45 and pro-collagen I was significantly reduced in the kidneys of Ang II-treated CXCR6-GFP knockin mice when compared with those of WT mice ( Figure 4A and 4B). These data indicate that CXCR6 has an important role in recruiting bone marrow-derived fibroblasts into the kidney in response to Ang II.
To determine whether CXCR6 disruption influences myofibroblast formation, kidney sections were stained for α-smooth muscle actin (α-SMA), a marker of myofibroblasts, and examined with a fluorescence microscope. Ang II-treated CXCR6-GFP knockin mice exhibited a significant reduction in the number of α-SMA + myofibroblasts in the kidneys when compared with Ang II-treated WT mice ( Figure 4C and 4D).
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WT wild-type Consistent with these findings, Western blot analysis showed that disruption of CXCR6 significantly reduced the protein expression levels of α-SMA in the kidneys after Ang II treatment when compared with WT mice ( Figure 4E and 4F).
Macrophage and T-Cell Infiltration and Inflammatory Cytokine Production
Recent evidence indicates that macrophages and T cells play a critical role in the pathogenesis of Ang II-induced target organ damage. 17 We examined whether infiltrating macrophages and T cells in the kidney express CXCR6. Kidney sections were stained for CXCR6 and F4/80, a macrophage marker, or CD3, a T-cell marker. The results showed that infiltrating F4/80 + macrophages and CD3 + T cells express CXCR6 ( Figure I in the online-only Data Supplement). To determine whether CXCR6 plays a role in the regulation of inflammatory cell infiltration into the kidney, WT and CXCR6-GFP knockin mice were infused with vehicle or Ang II for 2 weeks. Kidney sections were stained for F4/80 and CD3. Significant infiltration of macrophages and T cells was observed in the kidneys of WT mice after Ang II treatment when compared with the vehicle-treated control group. In contrast, disruption of CXCR6 significantly inhibited macrophage and T-cell infiltration into the kidneys after Ang II treatment ( Figure 5A-5D ).
These results indicate that CXCR6 mediates inflammatory cell infiltration into the kidney in Ang II-induced hypertensive kidney disease. We next examined the effect of CXCR6 disruption on the expression of known proinflammatory cytokines that are involved in the pathogenesis of kidney injury. 18 The mRNA levels of interleukin-6 (IL-6), tumor necrosis factor-α, IL-1β, and transforming growth factor-β1 were increased significantly in the kidneys of WT mice after Ang II treatment ( Figure 5E-5H) . In contrast, the upregulation of IL-6, tumor necrosis factor-α, IL-1β, and transforming growth factor-β1 was greatly attenuated in the kidneys of CXCR6-GFP knockin mice after Ang II treatment ( Figure 5E-5H ).
Effect of CXCR6 Disruption on Mobilization of Myeloid Fibroblasts Precursors, Monocytes, and T Cells
To determine the effect of CXCR6 disruption on mobilization of monocytes, T cells, and fibroblast precursors, peripheral nucleated cells were stained for CD11b and CD3 or CD45 and collagen I from WT and CXCR6-GFP knockin mice 2 weeks after saline or Ang II treatment. Our results showed that there were no significant differences among the 4 groups, although Ang II treatment led to a small but not significant increase in monocytes, T cells, and fibroblast precursors ( Figure II 
Effect of CXCR6 Disruption in Bone Marrow Cells on Accumulation of Myeloid Fibroblasts, Macrophages, and T Cells in the Kidney
To examine the role of CXCR6 in bone marrow-derived cells in recruiting myeloid fibroblasts, macrophages, and T cells further, we performed bone marrow chimera experiments by reconstitution of WT mice with CXCR6 +/+ or CXCR6 −/− bone marrow cells. Eight weeks after bone marrow transplantation, chimeric mice were subjected to vehicle or Ang II treatment for 2 weeks. The genotype of bone marrow-derived cells from the chimeric mice was confirmed by polymerase chain reaction of DNA extracted from peripheral blood cells ( Figure III in the online-only Data Supplement). When compared with WT mice transplanted with CXCR6 +/+ bone marrow cells, WT mice transplanted with CXCR6 −/− bone marrow cells accumulated fewer CD45 + and PDGFR-β + (platelet-derived growth factor receptor) fibroblasts, F4/80 + macrophages, and CD3 + T cells ( Figure 6 ). These data indicate that CXCR6 in bone marrow-derived cells is critical for 
Discussion
In this study, we have demonstrated that disruption of CXCR6 leads to renal protection in an experimental model of hypertensive kidney disease induced by Ang II. In the Ang II-induced hypertension model, disruption of CXCR6 preserves renal function, reduces urinary albumin excretion, and attenuates tubulointerstitial disease, glomerular injury, and vascular damage.
A large body of evidence indicates that activation of reninangiotensin system plays a central role in the initiation and progression of CKD. The underlying mechanisms involved in Ang II-induced hypertensive kidney disease are incompletely understood. Recent studies have shown that inflammatory and immune cell infiltration are characteristic for hypertensive kidney disease. 4, 5 The infiltration of circulating cells into sites of injury is mediated by locally produced chemokines through interaction with their respective receptors. We have recently shown that CXCL16 is induced in the kidney in response to Ang II, and CXCL16 deficiency suppresses Ang II-induced renal inflammation and fibrosis. 6 The CXCL16 receptor, CXCR6, is expressed in T cells, monocytes, and myeloid fibroblasts. [7] [8] [9] In the present study, we have demonstrated that CXCR6 is pathologically important in recruitment of myeloid fibroblasts, macrophages, and T cells and development of renal injury and fibrosis because disruption of CXCR6 inhibits recruitment of bone marrow-derived fibroblasts, macrophages, and T cells into the kidney and the development of renal interstitial fibrosis in response to Ang II treatment. Furthermore, when compared with WT mice transplanted with CXCR6 +/+ bone marrow cells, WT mice transplanted with CXCR6 −/− bone marrow cells accumulate fewer myeloid fibroblasts, macrophages, and T cells into the kidney. These data provide compelling evidence for a critical role of CXCR6 in recruiting myeloid fibroblasts, macrophages, and T cells into the kidney and pathogenesis of renal injury and fibrosis. Of note, CXCL16 knockout mice and CXCR6-GFP knockin displayed similar phenotype in response to Ang II treatment.
A novel finding of this study is the striking reduction in Ang II-induced renal fibrosis in CXCR6-GFP knockin mice. Renal fibrosis is a final common pathway leading to renal failure. Because activated fibroblasts are the principal effector cells that are responsible for extracellular matrix production in the fibrotic kidney, their activation is regarded as a key event in the pathogenesis of renal fibrosis. 19, 20 However, the origin of these fibroblasts remains debatable. They are traditionally thought to arise from resident renal fibroblasts. [21] [22] [23] Recent evidence suggests that they may originate from bone marrowderived fibroblast precursors. 9, [11] [12] [13] [14] [24] [25] [26] We and others have shown that these cells migrate into the kidney in response to obstructive injury and contribute to the development of renal fibrosis. 9, 12, [25] [26] [27] [28] However, the signaling mechanisms underlying the recruitment of these bone marrow-derived fibroblast precursors into the kidney are incompletely understood. In the present study, we showed that disruption of CXCR6 inhibits bone marrow-derived fibroblast accumulation and myofibroblast formation in the kidney and the development of renal fibrosis in response to Ang II. These results indicate that CXCR6 plays a key role in recruitment of bone marrowderived fibroblasts into the kidney and development of renal fibrosis in Ang II-induced hypertensive nephropathy.
Macrophages and T cells have been shown to play an important role in the development of hypertensive kidney disease. 17 Ang II is a key factor in the regulation of inflammatory response in hypertensive end-organ damage. 3, 29 CXCR6 is expressed in various leukocyte subsets, including monocytes and T cells. [7] [8] [9] Recent studies have shown that CXCR6 plays an important role in inflammatory disease, such as atherosclerosis. 30 In the present study, our results show that Ang IIinduced interstitial infiltration of macrophages and T cells into the kidney is significantly attenuated in CXCR6-GFP knockin mice. These data indicate that CXCR6 signaling mediates Ang II-induced macrophage and T-cell infiltration.
Our results indicate that disruption of CXCR6 significantly attenuates proinflammatory and profibrotic cytokine expression in the kidney in response to Ang II. This is relevant because proinflammatory cytokines, tumor necrosis factor-α, IL-6, and IL-1β, have been implicated in the pathogenesis of Ang II-induced target organ damage, 31 and transforming growth factor-β1 functions as a downstream mediator of Ang II-induced renal fibrosis. 3, 32 In summary, our studies identify that CXCR6 critically regulates Ang II-induced renal injury and fibrosis. In response to Ang II, the activated CXCR6 signaling recruits myeloid fibroblasts, monocytes/macrophages, and T cells into the kidney, leading to proinflammatory and profibrotic cytokine production, renal injury, and fibrosis. These findings suggest that inhibition of CXCR6 signaling could constitute a novel therapeutic target for hypertensive kidney disease. Figure 6 . CXCR6 disruption in bone marrowderived cells inhibits myeloid fibroblast, macrophage, and T-cell infiltration into the kidney. A, Representative photomicrographs of kidney sections stained for CD45 (red), platelet-derived growth factor receptor (PDGFR)-β (green), and DAPI (4',6-diamidino-2-phenylindole; blue). Arrowheads indicate CD45 and PDGFR-β double positive fibroblasts. Scale bar, 25 μm. B, Quantitative analysis of CD45 and PDGFR-β + fibroblasts in kidneys. **P<0.01 vs wild-type (WT) controls, +P<0.05 vs knockout (KO) Ang II, and #P<0.05 vs WT Ang II. n=5 per group. C, Representative photomicrographs of kidney sections from WT mice transplanted with CXCR6 +/+ or CXCR6 −/− bone marrow cells 2 weeks after Ang II or saline treatment stained for F4/80 (brown) and counterstained with hematoxylin (blue). Scale bar, 50 μm. D, Quantitative analysis of F4/80 + macrophages in the kidneys. **P<0.01 vs WT controls; #P<0.05 vs WT Ang II; +P<0.05 vs knockout (KO) Ang II. n=5 in each group. E, Representative photomicrographs of kidney sections stained for CD3 (brown) and counterstained with hematoxylin (blue). Scale bar, 50 μm. F, Quantitative analysis of CD3 + T cells in the kidneys. **P<0.01 vs WT controls; #P<0.05 vs WT Ang II; +P<0.05 vs KO Ang II. n=5 in each group. CON indicates control; and HPF, high-power field.
